All News

Recent cancer research has been able to allow doctors to know what treatments work in certain patients—and what treatment don’t.

Adding Avastin (bevacizumab) to standard chemotherapy after surgery failed to extend the time early-stage colon cancer patients were free of recurrence.

For the first time, a test can predict which patients with stage 2 colon cancer are more likely to have a recurrence.

Adding Avastin to standard therapy delays progression of advanced HER2-negative breast cancer in women without prior treatment.

A large phase III study examining whether the addition of Tarceva (erlotinib) to Avastin (bevacizumab) delayed progression of advanced non-small cell lung cancer reached its primary goal.

Results from an international study challenge current practice of screening for ovarian cancer relapse.

Researchers of a follicular lymphoma trial hope that BiovaxID, a personalized vaccine, could help delay recurrences.

The breast cancer drug Herceptin (trastuzumab) extends survival in certain gastric cancer patients by almost three months, according to a phase III international study.

Taking tamoxifen at the same time as certain drugs that treat depression and hot flashes may reduce the cancer drug’s ability to prevent breast cancer recurrence.

An international phase III trial found the investigational lung cancer drug, Zactima (vandetanib), significantly slowed the time a patient’s advanced lung cancer progressed.

A new class of drugs called PARP inhibitors is getting some serious attention in metastatic triple-negative breast cancers.